These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 24807367

  • 21. Switching previous therapies for Alzheimer's disease to galantamine.
    Ferris SH.
    Clin Ther; 2001; 23 Suppl A():A3-7. PubMed ID: 11396869
    [Abstract] [Full Text] [Related]

  • 22. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M.
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. An update on the pharmacology of galantamine.
    Villarroya M, García AG, Marco-Contelles J, López MG.
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG, Li B, Darvesh S, Lockridge O.
    Toxicology; 2007 Apr 20; 233(1-3):60-9. PubMed ID: 17194517
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.
    Cacabelos R.
    Expert Opin Drug Metab Toxicol; 2020 Aug 20; 16(8):673-701. PubMed ID: 32520597
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
    Macdonald IR, Rockwood K, Martin E, Darvesh S.
    J Alzheimers Dis; 2014 Aug 20; 42(2):379-84. PubMed ID: 24898642
    [Abstract] [Full Text] [Related]

  • 36. The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease.
    Gongadze N, Antelava N, Kezeli T, Okudjava M, Pachkoria K.
    Georgian Med News; 2008 Feb 20; (155):44-8. PubMed ID: 18401056
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Serum adipokine levels modified by donepezil treatment in Alzheimer's disease.
    Pákáski M, Fehér A, Juhász A, Drótos G, Fazekas OC, Kovács J, Janka Z, Kálmán J.
    J Alzheimers Dis; 2014 Feb 20; 38(2):371-7. PubMed ID: 23979024
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.